Drug Profile

ABT 201

Alternative Names: ABT-201

Latest Information Update: 18 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 Oct 2022 AnBogen Therapeutics plans to initiate phase I/II clinica trial for Non-small cell lung cancer and other Cancers in 2026 (AnBogen Therapeutics pipeline, October 2022)
21 Sep 2022 Anbogen Therapeutics plans IND-enabling studies for Non-small cell lung cancer and cancer by 2024 (Anbogen Therapeutics Pipeline, September 2022)
20 Sep 2022 Early research in Cancer in Taiwan (unspecified route) (Anbogen Therapeutics Pipeline, September 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com